A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
Leuk Lymphoma
; 63(5): 1058-1069, 2022 05.
Article
in En
| MEDLINE
| ID: mdl-35045765
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Waldenstrom Macroglobulinemia
/
Lymphoma, B-Cell, Marginal Zone
Limits:
Adult
/
Humans
Language:
En
Journal:
Leuk Lymphoma
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2022
Type:
Article
Affiliation country:
Greece